AKBA Q1 2018 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M+120.1% YoY

Gross Profit

-$15M-33.7% margin

Operating Income

-$24M-53.3% margin

Net Income

-$23M-51.0% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

-47.4%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$443M

Total Liabilities

$246M

Stockholders' Equity

$197M

Cash & Equivalents

$158M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$21M	+120.1%
Gross Profit	-$15M	-$39M	+60.5%
Operating Income	-$24M	-$45M	+45.5%
Net Income	-$23M	-$45M	+47.4%